Effect of lipid-arabinomannan (z-100) on the growth of human cervical carcinoma in scid mice inoculated with human lymphocytes

M. Kobavashi, R. B. Pollard, Fujio Suzuki

Research output: Contribution to journalArticle

Abstract

Antitumor activities of Z-100, an itnmunopotentiator extracted from M. tuberculosis, has been shown in man and animais bearing various malignancies. In the present study the influence of Z-100 on the growth of xenogeneic tumors (human SiHa cervical carcinoma cells, SiHa cells) in SCID mice inoculated with peripheral blood lymphocytes (PBL) from healthy volunteers were examined. SCID mice (BALB/c origin) inoculated with PBL (1 x 107 cells/mouse, i.v.) from healthy volunteers (hu-PBLSCID mice) were implanted with SiHa cells (2 x 106 cells/mouse, s.c., 3 days after PBL inoculation). Then, they were treated s.c. with a mixture of IL-4 (100 ng/mouse) and IL-10 ( 100 ng/mouse) every 5 days in combination with or without Z-100 (Zeria Pharmaceutical Co., Ltd., Tokyo, Japan, 0.1 100 fig/kg, s.c.) every other day beginning one day after tumor inoculation. Xenogeneic SiHa cells were completely eliminated in hu-PBL-SCID mice. However, SiHa cells inoculated in hu-PBL-SCID mice grew, at the same levels observed in SCID mice treated with saline, when mice were treated with a mixture of type 2 cytokines. When tumor-bearing hu-PBL-SCID mice received the mixture of type 2 cytokines in combination with Z-100, at doses of 1-100 (ig/kg, 71-89% of the tumor growth was suppressed, as compared with the tumor growth in hu-PBL-SCID mice treated with only type 2 cytokines. These doses of Z-100 did not show any antitumor activities to SiHa cells directly in vivo and in vitro. These results suggest that Z-100 may have a potential on the protective immunity influenced by type 2 cytokines in cancer patients.

Original languageEnglish (US)
JournalFASEB Journal
Volume10
Issue number6
StatePublished - 1996

Fingerprint

uterine cervical neoplasms
human growth
SCID Mice
Lymphocytes
Blood
lymphocytes
Carcinoma
Lipids
Tumors
mice
lipids
Growth
Bearings (structural)
Neoplasms
Cytokines
blood
neoplasms
cytokines
Healthy Volunteers
cells

ASJC Scopus subject areas

  • Agricultural and Biological Sciences (miscellaneous)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Biochemistry
  • Cell Biology

Cite this

Effect of lipid-arabinomannan (z-100) on the growth of human cervical carcinoma in scid mice inoculated with human lymphocytes. / Kobavashi, M.; Pollard, R. B.; Suzuki, Fujio.

In: FASEB Journal, Vol. 10, No. 6, 1996.

Research output: Contribution to journalArticle

@article{434bb33ac3604b1988349d1e38c6a4f3,
title = "Effect of lipid-arabinomannan (z-100) on the growth of human cervical carcinoma in scid mice inoculated with human lymphocytes",
abstract = "Antitumor activities of Z-100, an itnmunopotentiator extracted from M. tuberculosis, has been shown in man and animais bearing various malignancies. In the present study the influence of Z-100 on the growth of xenogeneic tumors (human SiHa cervical carcinoma cells, SiHa cells) in SCID mice inoculated with peripheral blood lymphocytes (PBL) from healthy volunteers were examined. SCID mice (BALB/c origin) inoculated with PBL (1 x 107 cells/mouse, i.v.) from healthy volunteers (hu-PBLSCID mice) were implanted with SiHa cells (2 x 106 cells/mouse, s.c., 3 days after PBL inoculation). Then, they were treated s.c. with a mixture of IL-4 (100 ng/mouse) and IL-10 ( 100 ng/mouse) every 5 days in combination with or without Z-100 (Zeria Pharmaceutical Co., Ltd., Tokyo, Japan, 0.1 100 fig/kg, s.c.) every other day beginning one day after tumor inoculation. Xenogeneic SiHa cells were completely eliminated in hu-PBL-SCID mice. However, SiHa cells inoculated in hu-PBL-SCID mice grew, at the same levels observed in SCID mice treated with saline, when mice were treated with a mixture of type 2 cytokines. When tumor-bearing hu-PBL-SCID mice received the mixture of type 2 cytokines in combination with Z-100, at doses of 1-100 (ig/kg, 71-89{\%} of the tumor growth was suppressed, as compared with the tumor growth in hu-PBL-SCID mice treated with only type 2 cytokines. These doses of Z-100 did not show any antitumor activities to SiHa cells directly in vivo and in vitro. These results suggest that Z-100 may have a potential on the protective immunity influenced by type 2 cytokines in cancer patients.",
author = "M. Kobavashi and Pollard, {R. B.} and Fujio Suzuki",
year = "1996",
language = "English (US)",
volume = "10",
journal = "FASEB Journal",
issn = "0892-6638",
publisher = "FASEB",
number = "6",

}

TY - JOUR

T1 - Effect of lipid-arabinomannan (z-100) on the growth of human cervical carcinoma in scid mice inoculated with human lymphocytes

AU - Kobavashi, M.

AU - Pollard, R. B.

AU - Suzuki, Fujio

PY - 1996

Y1 - 1996

N2 - Antitumor activities of Z-100, an itnmunopotentiator extracted from M. tuberculosis, has been shown in man and animais bearing various malignancies. In the present study the influence of Z-100 on the growth of xenogeneic tumors (human SiHa cervical carcinoma cells, SiHa cells) in SCID mice inoculated with peripheral blood lymphocytes (PBL) from healthy volunteers were examined. SCID mice (BALB/c origin) inoculated with PBL (1 x 107 cells/mouse, i.v.) from healthy volunteers (hu-PBLSCID mice) were implanted with SiHa cells (2 x 106 cells/mouse, s.c., 3 days after PBL inoculation). Then, they were treated s.c. with a mixture of IL-4 (100 ng/mouse) and IL-10 ( 100 ng/mouse) every 5 days in combination with or without Z-100 (Zeria Pharmaceutical Co., Ltd., Tokyo, Japan, 0.1 100 fig/kg, s.c.) every other day beginning one day after tumor inoculation. Xenogeneic SiHa cells were completely eliminated in hu-PBL-SCID mice. However, SiHa cells inoculated in hu-PBL-SCID mice grew, at the same levels observed in SCID mice treated with saline, when mice were treated with a mixture of type 2 cytokines. When tumor-bearing hu-PBL-SCID mice received the mixture of type 2 cytokines in combination with Z-100, at doses of 1-100 (ig/kg, 71-89% of the tumor growth was suppressed, as compared with the tumor growth in hu-PBL-SCID mice treated with only type 2 cytokines. These doses of Z-100 did not show any antitumor activities to SiHa cells directly in vivo and in vitro. These results suggest that Z-100 may have a potential on the protective immunity influenced by type 2 cytokines in cancer patients.

AB - Antitumor activities of Z-100, an itnmunopotentiator extracted from M. tuberculosis, has been shown in man and animais bearing various malignancies. In the present study the influence of Z-100 on the growth of xenogeneic tumors (human SiHa cervical carcinoma cells, SiHa cells) in SCID mice inoculated with peripheral blood lymphocytes (PBL) from healthy volunteers were examined. SCID mice (BALB/c origin) inoculated with PBL (1 x 107 cells/mouse, i.v.) from healthy volunteers (hu-PBLSCID mice) were implanted with SiHa cells (2 x 106 cells/mouse, s.c., 3 days after PBL inoculation). Then, they were treated s.c. with a mixture of IL-4 (100 ng/mouse) and IL-10 ( 100 ng/mouse) every 5 days in combination with or without Z-100 (Zeria Pharmaceutical Co., Ltd., Tokyo, Japan, 0.1 100 fig/kg, s.c.) every other day beginning one day after tumor inoculation. Xenogeneic SiHa cells were completely eliminated in hu-PBL-SCID mice. However, SiHa cells inoculated in hu-PBL-SCID mice grew, at the same levels observed in SCID mice treated with saline, when mice were treated with a mixture of type 2 cytokines. When tumor-bearing hu-PBL-SCID mice received the mixture of type 2 cytokines in combination with Z-100, at doses of 1-100 (ig/kg, 71-89% of the tumor growth was suppressed, as compared with the tumor growth in hu-PBL-SCID mice treated with only type 2 cytokines. These doses of Z-100 did not show any antitumor activities to SiHa cells directly in vivo and in vitro. These results suggest that Z-100 may have a potential on the protective immunity influenced by type 2 cytokines in cancer patients.

UR - http://www.scopus.com/inward/record.url?scp=33749150153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33749150153&partnerID=8YFLogxK

M3 - Article

VL - 10

JO - FASEB Journal

JF - FASEB Journal

SN - 0892-6638

IS - 6

ER -